The present invention is a cytocidal agent including a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 and a site selectively binding to a target molecule, in which the peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 is a peptide exclusively consisting of L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to the 14.sup.th amino acids are D-amino acids, and the 15.sup.th to 19.sup.th amino acids are L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to 14.sup.th amino acids are L-amino acids, and the 15.sup.th to the 19.sup.th amino acids are D-amino acids, or a peptide exclusively consisting of D-amino acids.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A9 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein that is greater than the level of expression of the BCL6 gene and/or protein of the control subject or population of control subjects.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of Substance P in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A6 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A12 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The present invention relates to methods of detecting CD200L in a female subject from a secretory phase biological sample. Increased levels of CD200L have been determined to be associated with endometriosis. CD200L is therefore a useful biomarker for the diagnosis of endometriosis and a useful target for therapeutic intervention.

Described herein are improved methods for the detection of endometriosis. Generally, the methods include, but are not limited to, applying machine learning algorithm to miRNA levels in order to detect, predict, diagnose, or monitor the presence or absence of endometriosis.

Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF, glycodelin and optionally ZAG, in a biological sample from the mammal, and determining that the mammal has endometriosis when the biomarker expression levels in the sample are elevated.